US FDA issued a draft guidance July 27 that the agency hopes will spur use of real-world evidence (RWE) and real-world data (RWD).
The guidelines, on how the agency plans to incorporate RWD into regulatory decision-making, comes as FDA has been championing the use of evidence sources such as registries to support pre-market and post-market device oversight. Meanwhile, the device industry
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?